Gene therapy for esophageal squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Advanced esophageal cancer, particularly T4 tumors, has a poor prognosis despite current treatments.
• Esophageal cancer exhibits specific genetic alterations, including p53 mutations and aberrant angiogenesis.
• Gene therapy offers a novel strategy targeting the molecular underpinnings of esophageal cancer.

Purpose of the Study:

• To review molecular events in esophageal cancer.
• To evaluate the efficacy of p53 gene therapy using Ad5CMV-p53 in esophageal cancer.
• To assess the tolerability and efficacy of p53 gene therapy in a clinical trial for unresectable advanced esophageal cancer.

Main Methods:

• Analysis of p53 genetic alterations and angiogenesis in esophageal cancer.
• In vitro evaluation of Ad5CMV-p53 (p53 recombinant adenoviral vector) on human esophageal squamous cell carcinoma cell lines.
• Phase I/II clinical trial enrolling 10 patients with unresectable advanced esophageal cancer to assess vector tolerability and efficacy.

Main Results:

• Ad5CMV-p53 infection led to significant growth suppression in human esophageal squamous cell carcinoma cell lines.
• The p53 gene therapy agent Ad5CMV-p53 demonstrates potential for locally advanced esophageal cancer.
• A Phase I/II clinical trial was initiated to evaluate p53 gene therapy in patients with unresectable advanced esophageal cancer.

Conclusions:

• Ad5CMV-p53 is a potential therapeutic agent for locally advanced esophageal cancer.
• Further research into combination gene therapies and adjuvant gene therapy with radiation is warranted.
• Clinical trials are essential for evaluating the safety and efficacy of p53 gene therapy in esophageal cancer patients.